CDT Equity announced that Sarborg Limited, in which CDT holds a 22.7% stake, has filed a patent for novel solid forms of a respiratory medicine. This development highlights the potential value of CDT's investment in Sarborg, which is currently valued at approximately $161 million based on Sarborg's latest capital raise.
CDT Equity is reporting on a patent filing by Sarborg Limited, a company in which CDT holds a significant 22.7% stake. This patent covers novel solid forms of a major respiratory medicine, an asset class with a large market potential. The filing itself is a positive development for Sarborg, and by extension, for CDT due to its substantial ownership. The filing also provides an updated valuation of CDT's holding in Sarborg at $161 million, which could positively impact CDT's perceived asset value. While the patent filing is a long-term development, the immediate impact for CDT is the re-affirmation of its investment's value and the potential for future growth if Sarborg's medicine progresses.